Suchergebnisse - "rucaparib"

PubPharm (404)

91

Imaging PARP with [18F]rucaparib in pancreatic cancer models

enthalten in: European journal of nuclear medicine and molecular imaging | 2022

von Chan, C. | Chen, Z. | Destro, G. | +9

92

Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Green, M. | Ma, S. | Goble, S. | +6

93

PARP inhibitors : clinical relevance and the role of multidisciplinary cancer teams on drug safety

enthalten in: Expert opinion on drug safety | 2022

von Jesus, M. | Morgado, M. | Duarte, A.

94

Appropriate Selection of PARP Inhibitors in Ovarian Cancer

enthalten in: Current treatment options in oncology | 2022

von Smith, M. | Pothuri, B.

95

Appropriate Selection of PARP Inhibitors in Ovarian Cancer

enthalten in: Current treatment options in oncology | 2022

von Smith, M. | Pothuri, B.

96

Appropriate Selection of PARP Inhibitors in Ovarian Cancer

enthalten in: Current treatment options in oncology | 2022

von Smith, M. | Pothuri, B.

97

Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Green, M. | Ma, S. | Goble, S. | +6

98

Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Green, M. | Ma, S. | Goble, S. | +6

99

Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Green, M. | Ma, S. | Goble, S. | +6

100

Rucaparib for BRCA1/2-mutated pretreated ovarian cancer : reflections from the ARIEL4 trial

enthalten in: The Lancet. Oncology | 2022

von O'Donnell, D.

CommentOn: Lancet Oncol. 2022 Apr;23(4):465-478. - PMID 35298906